Endovasc's CEO to Attend Second Annual ''Lipids, Liposomes & Biomembranes'' Conference
Liposomes are the basis of Endovasc's leading drug candidate, Liprostin, for the treatment of vascular disease. Dr. Dottavio will present an abstract entitled "Administration of Liprostin for the Treatment of Peripheral Vascular Disease (PVD)". Liprostin, a liposomal formulation of PGE-1, changes the drug's dynamics and improves its therapeutic index in ways that PGE-1 alone could not achieve. In clinical trials, patients with PVD showed a dramatic increase in walking distance and reduction in pain.
“Administration of Liprostin for the Treatment of Peripheral Vascular Disease (PVD)”
"This conference is being organized by some of the most exciting leaders in the field of liposomes and biomembranes. I look forward to presenting the abstract highlighting the success of our Phase II trials of Liprostin to treat people with PVD. This conference offers Endovasc an opportunity to showcase our liposomal nanotechnology, which we believe has the potential to positively impact many areas of treatment for vascular disease and wound healing."
For more information regarding the "Lipids, Liposomes, and Biomembranes 2005: New Technologies" Conference visit www.liposomesandmembranes.com.
Endovasc, Inc., established in 1996, is a Business Development Company focused on acquiring and investing in innovative drug development in the areas of cardiovascular and metabolic medicine. Endovasc's subsidiaries include; Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Nutraceutical Development Corporation which has an agreement in place with an innovative product development company to commercialize its muscle mass enhancing product; and Prostent, a stent coating technology.
For more information about Endovasc, please visit www.endovasc.com.
Safe Harbor Statement
The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com.